Literature DB >> 20824734

Metric properties of the mini-mental Parkinson and SCOPA-COG scales for rating cognitive deterioration in Parkinson's disease.

Marcos Serrano-Dueñas1, Belén Calero, Soledad Serrano, Maite Serrano, Paulina Coronel.   

Abstract

UNLABELLED: Parkinson's disease (PD) is a chronic neurodegenerative disorder that causes cognitive impairment and dementia in ∼30% of patients.
OBJECTIVE: Compare metric qualities of Mini-Mental Parkinson (MMP) and scales for outcomes in Parkinson's disease-cognition (SCOPA-COG) with respect to their relative reliability, validity and ability to predict symptoms (mobility, quality of life, social repercussions, and mood) in PD patients. Outpatients (n=123, 78 males/45 females) diagnosed with PD were included in the study. A multilevel (hierarchical) modeling analysis was performed along with tests of reliability and validity to ascertain which of the two models better predicts symptoms related to PD.
RESULTS: The MMP differed significantly between patients with Hoehn and Yahr (H&Y) stages 1, 2 or versus 4/5 (grouped together). The SCOPA-COG showed differences only between patients in H&Y stages 2 versus 4/5. Both scales were dependent on educational background and age. The SCOPA-COG had a higher coefficient of variation (0.303) than the MMP (0.184), indicating that it was the more discriminative of the two.
CONCLUSIONS: The SCOPA-COG has some advantages over the MMP, the most important being a greater discriminative ability. Multilevel hierarchical analysis clarified the necessity of stratifying the PD population according to educational background, years of illness, and H&Y stage when using these scales.
© 2010 Movement Disorder Society.

Entities:  

Mesh:

Year:  2010        PMID: 20824734     DOI: 10.1002/mds.23322

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

1.  Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog).

Authors:  V Isella; C Mapelli; N Morielli; D De Gaspari; C Siri; G Pezzoli; A Antonini; M Poletti; U Bonuccelli; L Picchi; A Napolitano; M Vista; M Veglia; F Piamarta; F Grassi; I M Appollonio
Journal:  Funct Neurol       Date:  2013 Apr-May

2.  Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease.

Authors:  V Isella; C Mapelli; N Morielli; D De Gaspari; C Siri; G Pezzoli; A Antonini; M Poletti; U Bonuccelli; L Picchi; A Napolitano; M Vista; A Greco; I M Appollonio
Journal:  Neurol Sci       Date:  2013-02-20       Impact factor: 3.307

3.  Mini mental Parkinson test: standardization and normative data on an Italian sample.

Authors:  Alberto Costa; Eriola Bagoj; Marco Monaco; Silvia Zabberoni; Salvatore De Rosa; Ciro Mundi; Carlo Caltagirone; Giovanni Augusto Carlesimo
Journal:  Neurol Sci       Date:  2013-03-12       Impact factor: 3.307

4.  Validation of Revised Chinese Version of PD-CRS in Parkinson's Disease Patients.

Authors:  Yuyan Tan; Weiguo Liu; Juanjuan Du; Miaomiao Hou; Cuiyu Yu; Yang Liu; Shishuang Cui; Lei Yan; Yizhou Lu; Hong Lv; Lijun Han; Xi Wang; Shengyu Zha; Xiaoguang Luo; Huidong Tang; Shengdi Chen
Journal:  Parkinsons Dis       Date:  2020-02-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.